Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic
Nimble Therapeutics Adds Peptide Drug Development Expertise to Board of Directors
Roche is making sure its peptide discovery spinout Nimble Therapeutics stays close with a revision of the companies’ development partnership.
MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics, a biotechnology company leveraging its next-generation peptide discovery platform to identify medicines for challenging-to-drug targets, today announced that the company has expanded its collaboration and executed a license agreement with Genentech, a member of the Roche Group (SIX:RO, ROG; OTCQX: RHHBY), for the discovery of peptide therapies for the treatment of diseases across multiple therapeutic areas.
Nimble Therapeutics Delivers Lead Compounds for Two Programs Under Collaboration with Large Pharma Partner, Triggering Milestone Payments
Nimble Therapeutics names Pete Gough as Chief Scientific Officer
MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics Inc. today announced the company has achieved the first development milestone for each of several programs attached to a multi-target collaboration with an undisclosed large pharma partner.
MADISON, Wis.--(BUSINESS WIRE)--Nimble Therapeutics, a biotechnology company revolutionizing the discovery and development of peptide therapeutics, today announced their strategic research collaboration with Incyte (NASDAQ: INCY) has been expanded to include discovery of additional novel peptide therapies.
Nimble Therapeutics, an industry-leading peptide therapeutic discovery and optimization company, today announced the appointment of Dr. Cyrus Arman as Chief Business Officer. Cyrus will be responsible for structuring strategic alliances, licensing agreements, and financial investments, and will further provide management and strategic leadership to the organization. The appointment comes at a time of significant growth for Nimble Therapeutics, as the company continues to advance its technology platform and build out its strategic partnerships. His appointment represents the first step in Nimble’s expansion toward becoming a fully integrated biotechnology company.
Nimble Therapeutics and RayzeBio today announced the companies have entered a strategic collaboration to discover and develop novel peptide-based radiopharmaceuticals for treatment of cancer.